Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks

Area of Science:

• Oncology
• Molecular Biology
• Systems Biology

Background:

• Signaling pathway complexity and oncogene perturbation hinder traditional disease research.
• Targeted drug therapies require understanding pathway rewiring for specificity and efficacy.

Purpose of the Study:

• To investigate the impact of time-staggered versus simultaneous EGFR inhibition combined with chemotherapy on triple-negative breast cancer cells.
• To explore systems-level approaches for dynamically rewiring oncogenic signaling pathways to enhance anti-cancer drug efficacy.

Main Methods:

• Utilized targeted inhibition of oncogenic signaling pathways and DNA-damaging chemotherapy.
• Employed high-density, time-dependent measurements of signaling networks, gene expression, and cell phenotypes.
• Applied mathematical modeling for systems-level analysis.

Main Results:

• Time-staggered epidermal growth factor receptor (EGFR) inhibition, but not simultaneous administration, significantly sensitized a subset of triple-negative breast cancer cells to genotoxic drugs.
• Systems-level analysis revealed dynamic rewiring of oncogenic signaling pathways.
• This rewiring converted cells to a less tumorigenic state, increasing susceptibility to DNA damage-induced cell death.

Conclusions:

• Dynamic rewiring of oncogenic signaling pathways offers a novel strategy for targeting tumors.
• Reactivation of extrinsic apoptotic pathways through timed drug intervention enhances cancer cell death.
• This approach holds promise for increasing the specificity and efficacy of cancer therapies.